Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bioflutin
- Development stage
- Unknown
- Lead developer
- Südmedica
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Bioflutin is an over-the-counter (OTC) oral drop formulation containing etilefrin hydrochloride, a sympathomimetic small molecule. Developed and marketed by Südmedica GmbH, it is primarily indicated for the treatment of orthostatic hypotension and circulatory regulation disorders associated with low blood pressure. The active ingredient, etilefrin, acts as an agonist on alpha- and beta-adrenergic receptors. By stimulating these receptors, the drug induces peripheral vasoconstriction and enhances cardiac contractility, leading to an increase in blood pressure and improvement in symptoms such as dizziness, weakness, and visual disturbances associated with postural changes.
- Brand names
- BioflutinBioflutin Tropfen
- Other names
- Bioflutin dropsBioflutin-Südmedica
Beyond the preview
Go deeper on Bioflutin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bioflutin.